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ABSTRACT
Objective: To test the effect of the single nucleotide polymorphism 66 TG (rs28357094) in
the osteopontin gene (SPP1) on functional measures over 12 months in Duchenne muscular dys-
trophy (DMD).
Methods: This study was conducted on a cohort of ambulatory patients with DMD from a network
of Italian neuromuscular centers, evaluated longitudinally with the North Star Ambulatory As-
sessment (NSAA) and the 6-Minute Walk Test (6MWT) at study entry and after 12 months. Geno-
type at rs28357094 was determined after completion of the clinical evaluations. Patients were
stratified in 2 groups according to a dominant model (TT homozygotes vs TG heterozygotes and
GG homozygotes) and clinical data were retrospectively compared between groups.
Results: Eighty patients were selected (age 4.1–19.3 years; mean 8.3  2.7 SD). There were no
differences in age or steroid treatment between the 2 subgroups. Paired t test showed a signifi-
cant difference in both NSAA (p  0.013) and 6MWT (p  0.03) between baseline and follow-up
after 12 months in patients with DMD carrying the G allele. The difference was not significant in
the T subgroup. The analysis of covariance using age and baseline values as covariate and SPP1
genotype as fixed effect showed that these parameters are significantly correlated with the 12-
month values.
Conclusions: These data provide evidence of the role of SPP1 genotype as a disease modifier in
DMD and support its relevance in the selection of homogeneous groups of patients for future
clinical trials. Neurology® 2012;79:159–162
GLOSSARY
6MWT6-MinuteWalk Test;ANCOVA analysis of covariance;DMDDuchennemuscular dystrophy;NSAANorth Star
Ambulatory Assessment.
Osteopontin (secreted phosphoprotein, SPP1), a 35–60 kDa secreted glycoprotein, functions
as a pleiotropic cytokine in several pathologic and reparative processes.1 Lately, evidence has
emerged that in the mdx mouse model SPP1 modulates muscle inflammation and regenera-
tion,2 and that SPP1 genetic ablation (“double mutant” mouse) induces a milder phenotype.3
We recently found that the polymorphic G genotype at position66 in the SPP1 promoter
(rs28357094) is associated with earlier loss of ambulation and more rapid weakness progression
in Duchenne muscular dystrophy (DMD).4 This association needs further confirmation and
assessment of magnitude and statistical power.5
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In the present study, we test the hypothesis
of the influence of the G genotype on disease
progression on a DMD cohort from 11 Ital-
ian centers (the Italian “North Star” Group).
This group has described various aspects of
DMD functional measures, such as the inter-
operator reliability of the North Star Ambula-
tory Assessment (NSAA),6 its correlation with
the 6-Minute Walk Test (6MWT),7 and the
longitudinal evaluation of these measures over
12 months.8
METHODS Inclusion criteria were as previously described8:
molecularly confirmed DMD diagnosis, ability to walk 75 me-
ters, absence of severe/moderate learning or behavioral problems,
and availability of a DNA sample.
Clinical evaluation with NSAA (score 0–34) and 6MWT
was performed at baseline (T0) and after 12 months if still am-
bulatory (T12), as previously described.6,9
Genotype at rs28357094 was determined by amplification
refractory mutation system,4 after clinical evaluations were com-
pleted (evaluators blind to genotype).
Patients were divided into 2 subgroups (dominant model):
wild-type homozygotes vs heterozygote/homozygote carriers of
rs28357094 (TT vs TG/GG). A recessive model (TT vs TG vs
GG) could not be adopted due to numerosity issues.
Age differences and functional changes over 12 months were
compared between subgroups with a t test for independent
groups. Distribution by steroid treatment was compared with a
2 test. Data normality was tested using the Kolmogorov-
Smirnov test. Paired t test was used to compare functional mea-
sures at T0 and T12 within each subgroup. Linear correlations
were tested using Pearson r. Analysis of covariance (ANCOVA)
was used to determine the cumulative effect of T0 functional
measures, age (covariates), and genotype (fixed effect) on func-
tional outcome at T12. A parallelism test was used to compare
linear regression slopes of functional measure changes relative
to age between subgroups. All measures are expressed as
mean  SD.
Standard protocol approvals, registrations, and patient
consents. Ethical standards committees on human experimen-
tation granted their approval in each institution, and informed
consent for research was obtained from all participating patients
or guardians of patients.
RESULTS Eighty patients were selected. Seventy-
seven were previously included in the multicentric
natural history study8 and 3 of these were also in-
cluded in the original report of SPP1 as a genetic
modifier of DMD.4 Mean age at T0 was 8.3  2.7
years (range 4.1–19.3).
Seventy-five patients (94%) were treated with ste-
roids; 49 (61%) received a continuous regimen (0.75
mg/kg prednisolone–0.9 mg/kg deflazacort daily or
equivalent8), and 26 (33%) an alternate regimen (10
days on-off, alternate days-weeks). Five patients
(6%) received no steroids. No patients were treated
with Losartan.
rs28357094 genotypes. A total of 57 patients were TT
homozygotes (71%, T subgroup), 18 TG heterozy-
gotes (23%), 5 GG homozygotes (6%). TG/GG pa-
tients were clustered in a subgroup of 23 patients
(29%, G subgroup).
In the T subgroup mean age was 8.5  2.9 years
(range 4.5–19.3). Fifty-four of 57 patients (95%) re-
ceived steroid treatment, 36/57 (63%) with a contin-
uous regimen and 18/57 (32%) with an alternate
regimen; 3/57 (5%) were not treated. In the G sub-
group mean age was 8.0  2.0 years (range 4.5–
11.8). Twenty-one of 23 patients (91%) received
steroid treatment, 13/23 (56%) with a continuous
regimen and 8/23 (35%) with an alternate regimen;
2/23 (9%) were not treated. Age (t test p  0.48)
or steroid treatment (2 test p  0.79) did not
differ significantly between the subgroups. No pa-
tients lost ambulation during follow-up, and all
were able to complete NSAA and 6MWT at T12.
The Kolmogorov-Smirnov test showed that both
NSAA and 6MWT values were normally distributed.
Mean NSAA T0–T12 scores were 23.3  7.2
and 22.2  8.2 (paired t test p  0.08) in the T
subgroup, and 24.6  6.3 and 21.5  7.6 (paired t
test p  0.013) in the G subgroup. Mean T0–T12
changes in NSAA score were 1.0  4.3 in the T
subgroup and 3.1  5.5 in the G subroup (p 
0.08) (table 1; figure).
Mean 6MWT T0–T12 distances were 368  86
and 360  98 meters (paired t test p  0.31) in the
T subgroup, and 387  67 and 343  124 meters
(paired t test p  0.03) in the G subgroup. Mean
6MWT T0–T12 changes were 8  61 meters in
the T subgroup and 44  89 meters in the G sub-
roup (p  0.04) (table 1; figure).
Table 1 NSAA and 6MWT at T0 and T12, mean SD
NSAA score 6MWT, m
Baseline 12mo Difference Baseline 12mo Difference
TT 23.3 7.2 22.2 8.2 1.0 4.3 368 86 360 98 8 61
TG/GG 24.6 6.3 21.5 7.6 3.1 5.5 387 67 343 124 44 89
Abbreviations: 6MWT 6-Minute Walk Test; NSAA North Star Ambulatory Assessment.
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Both NSAA and 6MWT values at T12 were lin-
early correlated with T0 values (r  0.81 for NSAA
and r 0.73 for 6MWT, p 0.0001). Moreover, in
the T subgroup both NSAA and 6MWT changes
over 12 months were inversely correlated with age
(r  0.48, p  0.0001; r  0.27, p  0.04),
while in the G subgroup the correlation was only
valid for NSAA (r  0.42, p  0.048), and not
for 6MWT. Parallelism tests of linear regressions
between functional changes and age showed a sig-
nificantly steeper decrease in the G subgroup for
both NSAA (p  0.001) and 6MWT (p  0.001)
(figure).
ANCOVA analysis showed that age and T0 func-
tional measures strongly determined T12 functional
outcome, which was also significantly and indepen-
dently influenced by genotype (NSAA p  0.030,
6MWT p  0.029, table 2).
DISCUSSION The discovery of SPP1 as a modifier
gene in DMD4 has relevant clinical implications, but
as noted,5 needs to be confirmed in larger popula-
tions. The natural history data collected by the Ital-
ian “North Star” network8 offered an opportunity to
test rs28357094 on an independent cohort (except
an overlap of 3 patients with our previous report4)
with validated, clinically meaningful functional mea-
sures, homogenous treatment standards, and longitu-
dinal data collection.
As hypothesized based on previous findings,4 pa-
tients in the G subgroup showed a significant decline
of NSAA and 6MWT at T12 (despite a slightly, non-
significantly better performance at T0), while the T
subgroup did not (figure).
We argue that the slight advantage of G patients at
baselinemay be due to their greater probability of losing
ambulation earlier, thus being excluded from the study.
As a consequence, relatively older patients with poor
baseline performance, but retaining independent ambu-
lation, are included in the T subgroup. This is sup-
ported by the narrower age range in the G subgroup: all
patients over 12 years carried the TT genotype (figure).
Figure PatientswithDuchennemuscular dystrophy carrying theGallele at rs28357094deteriorated faster thanpatients carrying theT allele
Themean values for North Star Ambulatory Assessment (NSAA) (A) and 6-MinuteWalk Test (6MWT) (B) at T0 and T12 in the T and G subgroups are shown.
T0–T12 mean differences in NSAA and 6MWT are significant only in the G subgroup of patients. Vertical bars represent 95% confidence intervals. A
scatterplot of T0–T12 changes in NSAA (C) and 6MWT (D) in the T andG subgroups are shown. The superimposed linear regression shows a steeper decline
in the G subgroup (NSAA slope estimates: T0.17, G1.12, SE: 0.13, p 0.001; 6MWT slope estimates: T5.76, G14.44, SE 2.02, p 0.001).
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The need to consider the influence of age and
functional performance at baseline together with
SPP1 genotype prompted us to develop a model
which could test the effect of different simultane-
ously acting factors in predicting functional outcome
after 12 months. ANCOVA analysis showed that
baseline measures and age are, as expected, highly
predictive of functional measures at T12, but SPP1
genotype retains an independent role, significantly
influencing the outcome. We could not implement
steroid treatment as a covariate in this model because
of the very few nontreated patients, who were how-
ever equally distributed between the subgroups.
It is well-documented that a high SD is intrinsic
to several DMD functional measures,7,9 and the pos-
sible drawbacks of such variability on assessing new
treatments are emerging, hence the need for criteria
for selecting homogeneous patient populations with
a predictable clinical course.
This study adds to the evidence that rs28357094
genotype influences functional outcome in DMD.
This may be relevant for the stratification of func-
tionally homogeneous patients when planning clini-
cal trials. Deeper insights into the underlying
molecular mechanisms will help our understanding
of the biological role of SPP1 in DMD.
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Table 2 Correlation coefficients and analysis of covariance for factors influencing functional outcome
NSAA at T12 6MWT at T12
Correlation
coefficients
ANCOVA
Correlation
coefficients
ANCOVAr b (SE) r b (SE)
Age 0.49 1.44 (0.29) p 105 0.38 14.86 (4.12) p 0.013
Corresponding baseline (T0) value 0.81 0.93 (0.08) p 106 0.73 0.97 (0.10) p 106
rs28357094 genotype (TT vs TG/GG) NA NA p 0.030 NA NA p 0.029
Abbreviations: 6MWT  6-Minute Walk Test; ANCOVA  analysis of covariance; NA  not applicable (in dichotomous
variables); NSAA North Star Ambulatory Assessment.
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